MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer

MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer

Summary: Advanced prostate cancers are treated with therapies targeting the androgen receptor (AR) signaling pathway. While many tumors initially respond to AR inhibition, nearly all develop resistance. It is critical to understand how prostate tumor cells respond to AR inhibition in order to exploi...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Preston D. Crowell, Jenna M. Giafaglione, Anthony E. Jones, Nicholas M. Nunley, Takao Hashimoto, Amelie M.L. Delcourt, Anton Petcherski, Raag Agrawal, Matthew J. Bernard, Johnny A. Diaz, Kylie Y. Heering, Rong Rong Huang, Jin-Yih Low, Nedas Matulionis, Nora M. Navone, Huihui Ye, Amina Zoubeidi, Heather R. Christofk, Matthew B. Rettig, Robert E. Reiter, Michael C. Haffner, Paul C. Boutros, Orian S. Shirihai, Ajit S. Divakaruni, Andrew S. Goldstein
Μορφή: Άρθρο
Γλώσσα:English
Έκδοση: Elsevier 2023-10-01
Σειρά:Cell Reports
Θέματα:
CP: Cancer
CP: Metabolism
Διαθέσιμο Online:http://www.sciencedirect.com/science/article/pii/S2211124723012330

Διαδίκτυο

http://www.sciencedirect.com/science/article/pii/S2211124723012330

Παρόμοια τεκμήρια